Financial Performance - In the first half of 2025, the company achieved operating revenue of 3.051 billion yuan, a year-on-year increase of 11.02% [2] - The net profit attributable to shareholders was 818 million yuan, reflecting a year-on-year growth of 10.74% [2] - The net profit after deducting non-recurring gains and losses was 788 million yuan, up 12.58% year-on-year [2] - The net cash flow from operating activities was 965 million yuan, an increase of 4.7% [2] - As of the end of June, the company's asset-liability ratio was 19.17%, with cash and cash equivalents amounting to 6.629 billion yuan [2] Dividend Distribution - The company plans to distribute a cash dividend of 12.69 yuan per 10 shares (tax included) to all shareholders, with a total expected cash dividend of 817 million yuan [2] - The cash dividend represents 117.01% of the net profit of the parent company for the first half of 2025 and 99.94% of the net profit attributable to shareholders [2] Business Strategy - The company focuses on the research, production, and sales of Ejiao and related traditional Chinese medicine products [2] - In response to increasing competition, the company aims to build a differentiated product layout, emphasizing convenience and ready-to-eat consumption experiences [2] - The company is committed to promoting industry standards and enhancing self-discipline within the Ejiao industry to ensure healthy development [2] Charitable Contribution - The company announced a plan to donate 4.3 million yuan to the China Women's Development Foundation, including a cash donation of 2.6 million yuan and in-kind donations valued at 1.7 million yuan [3] - This donation does not involve related party transactions and does not constitute a major asset restructuring as defined by regulations [4]